natgillin/translations-raw huggingface dataset:
Note: Selection of ADRs and their frequencies based on the 25 mg dose a Reflects MedDRA Preferred Terms of: “abdominal pain”, “abdominal pain upper”, “abdominal pain lower” and “gastrointestinal pain”.
Napomena: odabir nuspojava i njihovih učestalosti temelji se na primjeni doze od 25 mg. aOdnosi se na preferirane pojmove prema MedDRA-i za: “bol u abdomenu”, “bol u gornjem dijelu abdomena”, “bol u donjem dijelu abdomena” i “gastrointestinalna bol”.
Note: some air may remain in the pen, but this is not important as you have removed the air from the injection needle and the dose will be accurate.
Napomena: u brizgalici može ostati mala količina zraka, ali to nije važno jer ste uklonili zrak iz igle za injekciju pa će doza biti točna.
Note: Some patients may experience a mild sweet or slightly bitter taste, depending on the patient, when inhaling the medicine.
Napomena: Neki bolesnici će možda osjetiti blagi slatki ili neznatno gorki okus, ovisno o bolesniku, kod udisanja lijeka.
Note: Some patients may experience a mild sweet or slightly bitter taste, or grainy sensation, depending on the patient, when inhaling the medicinal product.
Napomena: Neki bolesnici će možda osjetiti blagi slatki ili neznatno gorki okus, ili osjećaj zrnatosti, ovisno o bolesniku, kod udisanja lijeka.
Note: Some patients may experience a mild sweet or slightly bitter taste, or grainy sensation, depending on the patient, when inhaling the medicine.
Napomena: Neki bolesnici će možda osjetiti blagi slatki ili neznatno gorki okus, ili osjećaj zrnatosti, ovisno o bolesniku, kod udisanja lijeka.
Note: The activation bar disappears and a small amount of liquid splashes out.
Napomena: aktivacijska traka nestaje, a štrcnut će mala količina tekućine.
NOTE: The cap contains a loose-fitting metal tube.
NAPOMENA: Na zatvaraču se nalazi labavi metalni cilindar.
Note: The colour of your KwikPen Dose Knob matches the insulin-specific colour band shown on the Pen Label.
Napomena: Boja gumba za doziranje na Vašem KwikPenu odgovara boji trake na naljepnici brizgalice i označava određenu vrstu inzulina.
NOTE: The final solution should be clear.
NAPOMENA: Pripremljena otopina mora biti bistra.
Note: The following variants were selected in cell culture but were not treatment-emergent: NS3 variants A156T in genotype 1a, and R155Q and D168H in genotype 1b; NS5A variants Y93C/H in genotype 1a, and L31F/V or Y93H in combination with L28M, L31F/V or P58S in genotype 1b; and NS5B variants Y448H in genotype 1a, and M414T and Y448H in genotype 1b.
Napomena: Sljedeće su varijante izdvojene u staničnoj kulturi, ali nisu se pojavile tijekom liječenja: NS3 varijante A156T u genotipu 1a te R155Q i D168H u genotipu 1b; NS5A varijante Y93C/H u genotipu 1a te L31F/V ili Y93H u kombinaciji s L28M, L31F/V ili P58S u genotipu 1b; NS5B varijante Y448H u genotipu 1a te M414T i Y448H u genotipu 1b.
NOTE: The injection should be administered immediately after mixing (if the injection is delayed, refrigerate the solution and inject it within 3 hours).
NAPOMENA: Injekciju treba primijeniti odmah nakon miješanja (ako odgodite primjenu injekcije, pohranite otopinu u hladnjak te ju injicirajte u roku od 3 sata).
NOTE: The injection should be administered immediately after mixing (if the injection is delayed, refrigerate the solution and inject it within 3 hours).
NAPOMENA: Injekciju treba primjeniti odmah nakon miješanja (ako odgodite primjenu injekcije, pohranite otopinu u hladnjak te ju injicirajte u roku od 3 sata).
Note: The interim OS analysis did not meet the protocol-specified early stopping boundary for OS (p = 0.0051). a Study PX-171-009
Napomena: Interim analiza OS-a nije dosegla protokolom specificirane granice ranog prekida za OS (p = 0,0051). a Ispitivanje PX-171-009
Note: The needle is covered by the needle cover and the needle will not be seen (see Figure D).
Napomena: Igla je pokrivena pokrovom igle i neće se vidjeti (vidjeti sliku D).
Note: The Nplate liquid is highly potent which is why accuracy and dose measurement are important.
Napomena: Otopina Nplate vrlo je potentna, zbog čega je važno točno izmjeriti dozu.
Note: the number of first events for the components CV death, MI and stroke are the actual number of first events for each component and do not add up to the number of events in the composite endpoint (s) Indicates statistical significance.
Napomena: broj prvih događaja za komponente KV smrt, IM i moždani udar su stvarni broj prvih događaja za svaku komponentu i ne zbrajaju se u broj događaja u kompozitnom ishodu.
Note: The pen will not allow you to dial more than the number of units left in the pen.
Napomena: Brizgalica ne dopušta da se odmjeri doza veća od broja jedinica preostalih u brizgalici.
Note: The plunger rod is not attached to the rubber stopper – this is to prevent air being drawn into the syringe.
Napomena: Potisni klip nije spojen na gumeni čep – time se sprečava uvlačenje zraka u štrcaljku.
Note: The pre-filled pen will make a clicking sound for up to 10 seconds – depending on your dose.
Napomena: Napunjena brizgalica će škljocati tijekom najviše 10 sekundi – ovisno o dozi.
NOTE: The required amount depends on the dose to be administered (0.2 ml to 1.0 ml).
NAPOMENA: Potrebna količina ovisi o dozi koju treba primijeniti (0,2 ml do 1,0 ml).
Note: The response and PD outcomes were determined using standard objective IMWG/EBMT response criteria. a Study PX-171-009
Napomena: Odgovor i PD ishodi su određeni primjenom standardnih objektivnih IMWG/EBMT kriterija odgovora a Ispitivanje PX-171-009
NOTE: There is no outer carton
NAPOMENA: Nema vanjskog pakovanja
NOTE: This medicine requires longer and more vigorous shaking than 1-monthly paliperidone palmitate injectable.
NAPOMENA: Ovaj lijek zahtijeva dulje i snažnije protresanje od paliperidonpalmitata u obliku 1- mjesečne injekcije.
Note: to preserve product sterility, it is important that the gas relief needle is not inserted through the vial closure before the product is dissolved.
Napomena: da bi se očuvala sterilnost lijeka, važno je ne uvoditi iglu za odvod plina kroz čep bočice prije nego se lijek ne otopi.
Note: Treatment failure at or after Week 6 (Study UV I), or at or after Week 2 (Study UV II), was counted as event.
Napomena: Neuspjeh liječenja u 6. tjednu ili nakon njega (ispitivanje UV I) odnosno u 2. tjednu ili nakon njega (ispitivanje UV II) smatrao se događajem.
Note: UT is the a.c. mains voltage prior to application of the test level.
Napomena: UT je mrežni izmjenični napon prije provedbe ispitivanja.
Note: You may not feel anything happen in your nose at all – do not trust this to mean the spray did not operate – rely on the click and number counter.
Napomena: Moguće je da niste osjetili kako se sprej raspršio u nosnicu - ali nemojte misliti da to znači da je sprej zatajio - oslanjajte se na 'klik' koji ste čuli i na ono što pokazuje prozorčić s brojačem.
Note: Your healthcare professional may recommend using a “Y” connector (for more than one site) or other needle set configuration.
Napomena: Vaš zdravstveni djelatnik može preporučiti uporabu ”Y” priključka (za više od jednog mjesta primjene infuzije) ili drugi komplet igle.
Notes on the instructions
Napomene uz upute
Notes on using the transfer device:
Napomene za korištenje pomagala za prijenos:
Notice swelling of your stomach area
metenost primijećeno oticanje u području trbuha
Notice the numbered marks on it.
Pregledajte numerirane oznake na njoj.
notice unusual bleeding or bruising [these may be symptoms of a decrease in blood platelets (thrombocytopenia), with a reduced ability of your blood to clot],
primijetite neuobičajeno krvarenje ili nastanak modrica [to mogu biti simptomi smanjenja broja krvnih pločica (trombocitopenije) sa smanjenom sposobnošću zgrušavanja krvi]
Notice unusual bleeding or bruising that may be (these may be symptoms of a decrease in blood platelets (thrombocytopenia), with a reduced ability of your blood to clot.
primijetite neuobičajeno krvarenje ili modrice (to mogu biti simptomi smanjenog broja trombocita u krvi [trombocitopenije]), uz smanjenu sposobnost zgrušavanja krvi.
Notice unusual bleeding or bruising that may be (these may be symptoms of a decrease in blood platelets(thrombocytopenia), with a reduced ability of your blood to clot.
primijetite neuobičajeno krvarenje ili modrice (to mogu biti simptomi smanjenog broja trombocita u krvi [trombocitopenije]), uz smanjenu sposobnost zgrušavanja krvi.
notice yellowing of your skin or eyes
ako primijetite da su vam požutjeli koža ili oči
Notice yellowing of your skin or eyes
žuta boja kože ili očiju
Notify your doctor as soon as possible if you have high blood pressure, headache, loss of sight.
Što prije obavijestite liječnika ako imate povišen krvni tlak, glavobolju ili gubitak vida.
Nottingham NG5 1PB
Nottingham
Novaquin 15 mg/ml oral suspension for horses Meloxicam
Novaquin 15 mg/ml peroralna suspenzija za konje Meloksikam
Novaquin contains meloxicam, which belongs to a class of medicines called non-steroidal anti- inflammatory drugs (NSAIDs).
Novaquin sadrži meloksikam, koji pripada skupini lijekova koji se zovu nesteroidni protuupalni lijekovi (NSAID).
Novaquin is a ‘generic medicine’.
Novaquin je „generički lijek”.
Novartis Europharm Limited Frimley Business Park Camberley GU16 7SR United Kingdom
Novartis Europharm Limited Frimley Business Park Camberley GU16 7SR Velika Britanija.
Novartis Hrvatska d.o.o.
Laboratório Medinfar - Produtos Farmacêuticos, S.A.
Novartis Pharmaceuticals UK Limited, Frimley Business Park, Frimley, Camberley, Surrey GU16 7SR, United Kingdom
Novartis Pharmaceuticals UK Limited, Frimley Business Park, Frimley, Camberley, Surrey GU16 7SR, Velika Britanija
Novartis V&D S.r.l. – Italy
Novartis V&D S.r.l. - Italija
Novartis V.I. S.r.l. - Italy Store in a refrigerator.
Novartis V.I. S.r.l. - Italija Čuvati u hladnjaku.
Novartis Vaccines and Diagnostics S.r.l. - Via Fiorentina, 1 – Siena, Italy.
Novartis Vaccines and Diagnostics S.r.l. - Via Fiorentina, 1 – Siena, Italija.
Novato, CA 94949 USA
Novato, CA 94949 SAD
Novem 20 mg/ml solution for injection for cattle and pigs
Novem 20 mg/ml otopina za injekcije za goveda i svinje
Novem 20 mg/ml solution for injection for cattle and pigs Meloxicam
Novem 20 mg/ml otopina za injekcije za goveda i svinje Meloksikam
Novem 5 mg/ml solution for injection for cattle and pigs Meloxicam
Novem 5 mg/ml otopina za injekcije za goveda i svinje Meloksikam
November 2020
studeni 2020.
Novo Nordisk A/S
Novo Nordisk A/S Novo Allé
Novo Nordisk A/S Brennum Park DK-3400 Hillerød Denmark
Novo Nordisk A/S Brennum Park DK-3400 Hillerød Danska
NovoEight 1000 IU powder and solvent for solution for injection
NovoEight 1000 IU prašak i otapalo za otopinu za injekciju
NovoEight 1000 IU powder for solution for injection turoctocog alfa
NovoEight 1000 IU prašak za otopinu za injekciju turoktokog alfa
NovoEight 1500 IU powder and solvent for solution for injection
NovoEight 1500 IU prašak i otapalo za otopinu za injekciju
NovoEight 1500 IU powder for solution for injection turoctocog alfa
NovoEight 1500 IU prašak za otopinu za injekciju turoktokog alfa
NovoEight 2000 IU powder and solvent for solution for injection
NovoEight 2000 IU prašak i otapalo za otopinu za injekciju
NovoEight 2000 IU powder for solution for injection turoctocog alfa
NovoEight 2000 IU prašak za otopinu za injekciju turoktokog alfa
NovoEight 250 IU powder for solution for injection turoctocog alfa
NovoEight 250 IU prašak za otopinu za injekciju turoktokog alfa
NovoEight 3000 IU powder and solvent for solution for injection
NovoEight 3000 IU prašak i otapalo za otopinu za injekciju
NovoEight 3000 IU powder for solution for injection turoctocog alfa
NovoEight 3000 IU prašak za otopinu za injekciju turoktokog alfa
NovoEight 500 IU powder and solvent for solution for injection
NovoEight 500 IU prašak i otapalo za otopinu za injekciju
NovoEight 500 IU powder for solution for injection turoctocog alfa
NovoEight 500 IU prašak za otopinu za injekciju turoktokog alfa
NovoEight can only be obtained with a prescription and treatment should be started under the supervision of a doctor who has experience in the treatment of haemophilia.
NovoEight se izdaje samo na liječnički recept, a liječenje treba započeti pod nadzorom liječnika s iskustvom u liječenju hemofilije.
NovoEight contains approximately 125 IU/ml of human coagulation factor VIII (rDNA), turoctocog alfa after reconstitution.
Nakon rekonstitucije, NovoEight sadrži približno 125 IU/ml humanog koagulacijskog faktora VIII (rDNK), turoktokoga alfa.
NovoEight contains approximately 250 IU/ml of human coagulation factor VIII (rDNA), turoctocog alfa after reconstitution.
Nakon rekonstitucije, NovoEight sadrži približno 250 IU/ml humanog koagulacijskog faktora VIII (rDNK), turoktokoga alfa.
NovoEight contains approximately 375 IU/ml of human coagulation factor VIII (rDNA), turoctocog alfa after reconstitution.
Nakon rekonstitucije, NovoEight sadrži približno 375 IU/ml humanog koagulacijskog faktora VIII (rDNK), turoktokoga alfa.
NovoEight contains approximately 500 IU/ml of human coagulation factor VIII (rDNA), turoctocog alfa after reconstitution.
Nakon rekonstitucije, NovoEight sadrži približno 500 IU/ml humanog koagulacijskog faktora VIII (rDNK), turoktokoga alfa.
NovoEight contains approximately 62.5 IU/ml of human coagulation factor VIII (rDNA), turoctocog alfa after reconstitution.
Nakon rekonstitucije, NovoEight sadrži približno 62,5 IU/ml humanog koagulacijskog faktora VIII (rDNK), turoktokoga alfa.
NovoEight contains approximately 750 IU/ml of human coagulation factor VIII (rDNA), turoctocog alfa after reconstitution.
Nakon rekonstitucije, NovoEight sadrži približno 750 IU/ml humanog koagulacijskog faktora VIII (rDNK), turoktokoga alfa.
NovoEight contains turoctocog alfa, a human coagulation factor VIII (rDNA), with a truncated B-domain.
NovoEight sadrži turoktokog alfa, humani koagulacijski faktor VIII (rDNK), sa skraćenom B-domenom.
NovoEight has been shown to be effective at preventing and treating bleeding episodes in two main studies involving a total of 213 patients with haemophilia A. None of the studies compared NovoEight with any other medicines.
Dokazano je da je NovoEight djelotvoran u sprječavanju i liječenju epizoda krvarenja u dva glavna ispitivanja koja su obuhvatila ukupno 213 bolesnika s hemofilijom A. Nijedno od provedenih ispitivanja nije usporedilo NovoEight s bilo kojim drugim lijekom.
NovoEight has no influence on your ability to drive and use machines.
NovoEight ne utječe na sposobnost upravljanja vozilima i rada sa strojevima.
NovoEight is a medicine that contains the active substance turoctocog alfa.
NovoEight je lijek koji sadrži djelatnu tvar turoktokog alfa.
NovoEight is available as a powder and solvent that are mixed together to make a solution for injection into a vein.
NovoEight je dostupan kao prašak i otapalo koji se miješaju zajedno i tvore otopinu za ubrizgavanje u venu.
NovoEight is available in packs containing 250, 500, 1000, 1500, 2000 or 3000 IU.
NovoEight je dostupan u pakiranjima koja sadrže 250, 500, 1000, 1500, 2000 ili 3000 IU.
NovoEight is given as an injection into a vein.
NovoEight se primjenjuje injekcijom u venu.
NovoEight is intended for either short-term or long-term use.
NovoEight predviđen je za kratkotrajnu ili dugotrajnu primjenu.
NovoEight is recommended to be used immediately after it has been reconstituted.
Preporučuje se primijeniti NovoEight odmah nakon pripreme za primjenu.
NovoEight is to be administered intravenously after reconstitution of the powder with the solvent supplied in the syringe.
NovoEight se primjenjuje intravenski nakon rekonstitucije praška s otapalom koje dolazi u štrcaljki.
NovoEight is used to correct the factor VIII deficiency by replacing the missing factor VIII, thereby giving temporary control of the bleeding disorder.
NovoEight koristi se za ispravljanje deficijencije faktora VIII tako što zamjenjuje faktor VIII koji nedostaje, čime se omogućuje privremena kontrola poremećaja krvarenja.
NovoEight must not be used in patients who are known to be allergic to hamster protein.
NovoEight ne smije se primjenjivati u bolesnika za koje je poznato da su alergični na protein hrčka.
NovoEight replaces this faulty or missing ‘factor VIII’ and helps blood to form clots at the site of bleeding.
NovoEight zamjenjuje taj ‘faktor VIII’ koji nedostaje ili ne djeluje pravilno te pomaže u stvaranju krvnih ugrušaka na mjestu krvarenja.
NovoEight turoctocog alfa
NovoEight turoktokog alfa
NovoEight was rated as ‘excellent’ or ‘good’ at treating 116 of the 126 bleeding episodes.
NovoEight je ocijenjen kao „odličan” ili „dobar” za liječenje 116 od 126 epizoda krvarenja.
NovoMix 30 can also be given in combination with oral antidiabetic medicinal products if the patient's blood glucose is inadequately controlled with oral antidiabetic medicinal products alone.
NovoMix 30 može se primjenjivati i u kombinaciji s oralnim antidijabeticima kada bolesnikove vrijednosti glukoze u krvi nisu dovoljno regulirane samo oralnim antidijabeticima.
NovoMix 30 can be used in adolescents and children aged 10 years and above when premixed insulin is preferred.
NovoMix 30 se može primjenjivati u adolescenata i djece u dobi od 10 ili više godina ako je predmiješani inzulin lijek izbora.
NovoMix 30 can be used in adolescents and children aged 10 years and above.
NovoMix 30 se može primjenjivati u adolescenata i djece u dobi od 10 ili više godina.
NovoMix 30 can be used in older patients; however there is limited experience with the use of NovoMix 30 in combination with oral antidiabetic medicinal products in patients older than 75 years.
NovoMix 30 se može koristiti u starijih bolesnika, no iskustvo primjene lijeka NovoMix 30 u kombinaciji s oralnim antidijabeticima u bolesnika starijih od 75 godina ograničeno je.
NovoMix 30 contains less than 1 mmol sodium (23 mg) per dose, i.e.
NovoMix 30 sadrži manje od 1 mmol (23 mg) natrija po dozi, tj.
NovoMix 30 FlexPen 100 units/ml Suspension for injection
NovoMix 30 FlexPen 100 jedinica/ml Suspenzija za injekciju
NovoMix 30 FlexPen 100 units/ml suspension for injection in a pre-filled pen
NovoMix 30 FlexPen 100 jedinica/ml suspenzija za injekciju u napunjenoj brizgalici
NovoMix 30 FlexPen 100 units/ml suspension for injection in pre-filled pen
NovoMix 30 FlexPen 100 jedinica/ml suspenzija za injekciju u napunjenoj brizgalici
NovoMix 30 FlexPen Glass ball
NovoMix 30 FlexPen Staklena
NovoMix 30 FlexPen is a pre-filled pen designed to be used with NovoFine or NovoTwist needles.
NovoMix 30 FlexPen je napunjena brizgalica namijenjena uporabi s iglama NovoFine ili NovoTwist.
NovoMix 30 FlexPen is a pre-filled, colour-coded, disposable pen containing a mixture of rapid- acting and intermediate-acting insulin aspart in the ratio 30/70.
NovoMix 30 FlexPen je jednokratna napunjena brizgalica označena bojom koja sadrži mješavinu brzodjelujućeg i srednjedugodjelujućeg aspart inzulina u omjeru 30/70.
NovoMix 30 FlexPen is colour-coded and accompanied by a package leaflet with detailed instructions for use to be followed.
NovoMix 30 FlexPen označen je bojom i uz njega je priložena Uputa o lijeku s detaljnim naputcima za primjenu koje valja slijediti.
NovoMix 30 is a biphasic suspension of the insulin analogue, insulin aspart.
NovoMix 30 je bifazična suspenzija inzulinskog analoga, aspart inzulina.
NovoMix 30 is a modern insulin (insulin analogue) with both a rapid-acting and an intermediate- acting effect, in the ratio 30/70.
NovoMix 30 je moderni inzulin (inzulinski analog) s brzodjelujućim i srednjedugodjelujućim učinkom, u omjeru 30/70.
NovoMix 30 is essentially ‘sodium-free’.
NovoMix 30 sadrži zanemarive količine natrija.
NovoMix 30 may be used in combination with tablets for diabetes.
NovoMix 30 se može primjenjivati u kombinaciji s tabletama protiv šećerne bolesti.
NovoMix 30 must not be administered intravenously, as it may result in severe hypoglycaemia.
NovoMix 30 se ne smije primjenjivati intravenski jer to može rezultirati teškom hipoglikemijom.
NovoMix 30 Penfill 100 units/ml Suspension for injection
NovoMix 30 Penfill 100 jedinica/ml Suspenzija za injekciju
NovoMix 30 Penfill 100 units/ml suspension for injection in a cartridge
NovoMix 30 Penfill 100 jedinica/ml suspenzija za injekciju u ulošku
NovoMix 30 Penfill 100 units/ml suspension for injection in cartridge
NovoMix 30 Penfill 100 jedinica/ml suspenzija za injekciju u ulošku
NovoMix 30 Penfill and NovoMix 30 FlexPen:
NovoMix 30 Penfill i NovoMix 30 FlexPen:
NovoMix 30 Penfill is accompanied by a package leaflet with detailed instructions for use to be followed.
Uz NovoMix 30 Penfill priložena je Uputa o lijeku s detaljnim naputcima za primjenu koje valja slijediti.
NovoMix 30 will start to lower your blood sugar 10–20 minutes after you inject it, the maximum effect occurs between 1 and 4 hours after the injection, and the effect lasts for up to 24 hours.
NovoMix 30 počinje snižavati razinu šećera u krvi 10–20 minuta nakon što ga injicirate, maksimalan učinak postiže se između 1 i 4 sata nakon injiciranja, a učinak traje do 24 sata.
NovoMix 50 contains less than 1 mmol sodium (23 mg) per dose, i.e.
NovoMix 50 sadrži manje od 1 mmol (23 mg) natrija po dozi, tj.
NovoMix 50 FlexPen 100 units/ml Suspension for injection
NovoMix 50 FlexPen 100 jedinica/ml Suspenzija za injekciju
NovoMix 50 FlexPen 100 units/ml suspension for injection in a pre-filled pen
NovoMix 50 FlexPen 100 jedinica/ml suspenzija za injekciju u napunjenoj brizgalici
NovoMix 50 FlexPen 100 units/ml Suspension for injection in pre-filled pen
NovoMix 50 FlexPen 100 jedinica/ml Suspenzija za injekciju u napunjenoj brizgalici
NovoMix 50 FlexPen Glass ball
NovoMix 50 FlexPen Staklena
NovoMix 50 FlexPen is a pre-filled pen designed to be used with NovoFine or NovoTwist needles.
NovoMix 50 FlexPen je napunjena brizgalica namijenjena uporabi s iglama NovoFine ili NovoTwist.
NovoMix 50 FlexPen is a pre-filled, colour-coded, disposable pen containing a mixture of rapid- acting and intermediate-acting insulin aspart in the ratio 50/50.
NovoMix 50 FlexPen je jednokratna napunjena brizgalica označena bojom koja sadrži mješavinu brzodjelujućeg i srednjedugodjelujućeg aspart inzulina u omjeru 50/50.
NovoMix 50 FlexPen is colour-coded and accompanied by a package leaflet with detailed instructions for use to be followed.
NovoMix 50 FlexPen označen je bojom i uz njega je priložena Uputa o lijeku s detaljnim naputcima za primjenu koje valja slijediti.
NovoMix 50 is a modern insulin (insulin analogue) with both a rapid-acting and an intermediate- acting effect, in the ratio 50/50.
NovoMix 50 je moderni inzulin (inzulinski analog) s brzodjelujućim i srednjedugodjelujućim učinkom, u omjeru 50/50.
NovoMix 50 is essentially ‘sodium-free’.
NovoMix 50 sadrži zanemarive količine natrija.
NovoMix 50 may fully or partially meet this requirement.
NovoMix 50 može u potpunosti ili djelomično nadoknaditi tu potrebu.
NovoMix 50 must not be administered intravenously, as it may result in severe hypoglycaemia.
NovoMix 50 se ne smije primjenjivati intravenski jer to može rezultirati teškom hipoglikemijom.
NovoMix 50 Penfill 100 units/ml Suspension for injection
NovoMix 50 Penfill 100 jedinica/ml Suspenzija za injekciju
NovoMix 50 Penfill 100 units/ml suspension for injection in a cartridge
NovoMix 50 Penfill 100 jedinica/ml suspenzija za injekciju u ulošku
NovoMix 50 Penfill 100 units/ml suspension for injection in cartridge
NovoMix 50 Penfill 100 jedinica/ml suspenzija za injekciju u ulošku
NovoMix 50 Penfill is accompanied by a package leaflet with detailed instructions for use to be followed.
Uz NovoMix 50 Penfill priložena je Uputa o lijeku s detaljnim naputcima za primjenu koje valja slijediti.
NovoMix 50 will start to lower your blood sugar 10–20 minutes after you inject it, the maximum effect occurs between 1 and 4 hours after the injection, and the effect lasts for up to 14–24 hours.
NovoMix 50 počinje snižavati razinu šećera u krvi 10–20 minuta nakon što ga injicirate, maksimalan učinak postiže se između 1 i 4 sata nakon injiciranja, a učinak traje do 14–24 sata.
NovoMix 70 contains less than 1 mmol sodium (23 mg) per dose, i.e.
NovoMix 70 sadrži manje od 1 mmol (23 mg) natrija po dozi, tj.
NovoMix 70 FlexPen 100 units/ml Suspension for injection
NovoMix 70 FlexPen 100 jedinica/ml Suspenzija za injekciju